TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
10x Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$69.89+0.03 (+0.04%)
Close on Oct 19, 2026
- Market cap
- $9.08B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
69.1%−11.4 pts over 5 years
Operating margin
-9.5%+169.2 pts over 5 years
Net margin
-6.8%+174.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.2% | +7.6% | +16.6% | – | |
| Gross profit | +7.1% | +3.9% | +13.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -93.6% | -5.8% | |
| Return on assets | – | -70.7% | -4.4% | |
| Current ratio | – | 6.56 | 4.46 | |
| Debt to equity | – | 0.00 | – | |
| Net debt to EBITDA | – | 1.32× | – | |
| Interest coverage | – | -317.6× | – | |
| Inventory turnover | – | 2.6× | 2.9× | |
| Capex to revenue | – | 12.3% | 0.9% | |
| Diluted shares | – | 101M | 125M |
Where the cash went
Fiscal 2021 to 2025, five years combined
10x Genomics generated $212.89M from operations and spent $299.87M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$212.89M
Used
$299.87M
Capital expenditure$299.87M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.8%
×Asset turnover0.66×
×Equity multiplier1.30×
=Return on equity, FY2025-5.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6.8% | 0.66× | 1.30× | -5.8% |
| FY2024 | -29.9% | 0.65× | 1.30× | -25.2% |
| FY2023 | -41.2% | 0.62× | 1.29× | -33.0% |
| FY2022 | -32.1% | 0.50× | 1.26× | -20.5% |
| FY2021 | -11.9% | 0.50× | 1.25× | -7.5% |
| FY2020 | -181.6% | 0.39× | 1.32× | -93.6% |
| FY2019 | -12.7% | 0.67× | 3.65× | -31.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$43.54M
- Cash generatingOperating cash flow above zero$136.05M
- Return on assets improvedROA up on the prior year-18.9% → -4.7%
- Earnings backed by cashOperating cash flow above net income$136.05M vs -$43.54M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.97 → 4.46
- No dilutionShare count did not rise120M → 125M
- Gross margin improvedGross margin up on the prior year67.86% → 69.05%
- More efficientAsset turnover rose0.63 → 0.70